X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2715) 2715
Publication (671) 671
Book / eBook (35) 35
Book Review (17) 17
Book Chapter (9) 9
Newspaper Article (4) 4
Magazine Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1977) 1977
index medicus (1338) 1338
female (1257) 1257
male (1149) 1149
hemic and lymphatic diseases (999) 999
animals (879) 879
middle aged (787) 787
adult (676) 676
oncology (613) 613
aged (573) 573
lymphatic metastasis (520) 520
cancer (471) 471
mice (461) 461
lymphatic diseases - chemically induced (354) 354
lymphatic system (323) 323
research article (301) 301
hematology (300) 300
chemotherapy (298) 298
article (295) 295
research (268) 268
leukemia (241) 241
antineoplastic combined chemotherapy protocols - adverse effects (240) 240
care and treatment (235) 235
treatment outcome (224) 224
antineoplastic combined chemotherapy protocols - therapeutic use (223) 223
health aspects (215) 215
rats (212) 212
metastasis (205) 205
antineoplastic agents - adverse effects (203) 203
gene expression (202) 202
proteins (201) 201
expression (199) 199
risk factors (197) 197
analysis (195) 195
apoptosis (195) 195
medicine (195) 195
adolescent (190) 190
therapy (180) 180
disease models, animal (177) 177
immunology (177) 177
aged, 80 and over (172) 172
prognosis (171) 171
tumors (167) 167
cell biology (157) 157
patients (155) 155
time factors (155) 155
cell line, tumor (151) 151
child (148) 148
multidisciplinary sciences (148) 148
inflammation (146) 146
immune system diseases (145) 145
rodents (142) 142
lymph nodes - pathology (141) 141
medicine, research & experimental (136) 136
follow-up studies (134) 134
development and progression (132) 132
breast cancer (131) 131
lymphomas (131) 131
mice, inbred c57bl (127) 127
science (127) 127
antineoplastic agents - therapeutic use (125) 125
disease-free survival (125) 125
neutropenia - chemically induced (120) 120
child, preschool (116) 116
neoplasm staging (116) 116
biochemistry & molecular biology (115) 115
survival (115) 115
abridged index medicus (114) 114
genetic aspects (114) 114
immunohistochemistry (113) 113
lymphoma (113) 113
breast neoplasms - drug therapy (112) 112
drug therapy (112) 112
kinases (112) 112
cancer therapies (111) 111
lymphocytes (111) 111
physiological aspects (111) 111
studies (111) 111
lymph nodes (110) 110
neoplasms (109) 109
pharmacology & pharmacy (108) 108
toxicity (107) 107
children (105) 105
retrospective studies (105) 105
surgery (105) 105
biology (104) 104
breast neoplasms - pathology (104) 104
dose-response relationship, drug (103) 103
pathology (102) 102
lymphatic diseases - pathology (100) 100
carcinoma (98) 98
activation (97) 97
risk (97) 97
signal transduction (97) 97
cells (95) 95
cytokines (95) 95
thrombocytopenia - chemically induced (95) 95
drug administration schedule (93) 93
mutation (93) 93
survival rate (93) 93
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2582) 2582
German (60) 60
French (37) 37
Russian (29) 29
Japanese (17) 17
Chinese (14) 14
Italian (5) 5
Spanish (5) 5
Hungarian (4) 4
Dutch (3) 3
Portuguese (2) 2
Arabic (1) 1
Croatian (1) 1
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Polish (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2691 - 2697
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been... 
REGRESSION | METASTATIC MELANOMA | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | EFFICACY | ONCOLOGY | PHASE-II | MONOCLONAL-ANTIBODY | CTLA-4 | PATIENT | CANCER-IMMUNOTHERAPY | BLOCKADE | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article
Chest, ISSN 0012-3692, 2016, Volume 149, Issue 5, pp. e133 - e136
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2473 - 2481
Summary Background In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | CLINICAL-TRIALS | CARDIOVASCULAR-DISEASE | PREVENTION | RISK | INTOLERANCE | PARTICIPANTS | Hematologic Diseases - chemically induced | Hypolipidemic Agents - adverse effects | Atorvastatin - adverse effects | Double-Blind Method | Nocebo Effect | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Atorvastatin - administration & dosage | Sleep Wake Disorders | Early Termination of Clinical Trials | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Lymphatic Diseases - chemically induced | Hypolipidemic Agents - administration & dosage | Hypertension - complications | Adult | Female | Hypercholesterolemia - prevention & control | Aged | Muscular Diseases - chemically induced | Clinical trials | Medicine, Experimental | Complications and side effects | Medical research | Epidemiology | Statins | Analysis | Cardiac patients | Sexual disorders | Risk factors | Myocardial infarction | Heart | Therapy | Laboratories | Funding | Physicians | Disorders | Impairment | Cognitive ability | Lipids | Cardiovascular disease | Angina | Matching | Connective tissues | Disturbance | Heart diseases | Public health | Hypertension | Medical personnel | Lymphatic system | Fasting | Effectiveness | Kidneys | Health risks | Erectile dysfunction | Risk analysis | Patients | Low density lipoprotein | Cholesterol | Doctors | Side effects | Sleep | Atorvastatin | Infarction | Health risk assessment | Cardiovascular diseases | Kidney transplantation | Clinical Medicine | management | clinical-trials | intolerance | risk | cardiovascular-disease | Klinisk medicin | General & Internal Medicine | prevention | participants
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 13, pp. 2578 - 2585
Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in... 
RHEUMATOID-ARTHRITIS | BCR | B-CELL LYMPHOMA | RESPONSE CRITERIA | R-CHOP | THERAPEUTIC TARGET | PHASE-III | TYROSINE KINASE INHIBITOR | FOLLICULAR LYMPHOMA | HEMATOLOGY | EXPRESSION | Humans | Middle Aged | Neoplasm Proteins - physiology | Salvage Therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Lymphoma, Non-Hodgkin - enzymology | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Protein-Tyrosine Kinases - physiology | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Oxazines - administration & dosage | Syk Kinase | Lymphoma, Non-Hodgkin - drug therapy | Oxazines - pharmacology | Pyridines - therapeutic use | Hematologic Diseases - chemically induced | Pyridines - administration & dosage | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Treatment Outcome | Oxazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Oxazines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Intracellular Signaling Peptides and Proteins - physiology | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Occupational and Environmental Medicine, ISSN 1351-0711, 05/2010, Volume 67, Issue 5, pp. 341 - 347
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1066 - 1073
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2014, Volume 9, Issue 10, p. e109332
Journal Article
Archives of Gynecology and Obstetrics, ISSN 0932-0067, 07/2010, Volume 282, Issue 1, pp. 83 - 88
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 18, pp. 4129 - 4132
In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This... 
B-CELLS | CRITERIA | VIRUS EBV DNA | STEM-CELLS | HEMATOLOGY | RECURRENT | Hodgkin Disease - virology | Lung Diseases - chemically induced | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Vinblastine - administration & dosage | Young Adult | Herpesvirus 4, Human - isolation & purification | Hodgkin Disease - radiotherapy | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Epstein-Barr Virus Infections | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | B-Lymphocyte Subsets - pathology | Kaplan-Meier Estimate | Rituximab | Survival Rate | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Clone Cells - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Gastrointestinal Diseases - chemically induced | Lymphoid Neoplasia | Clinical Trials and Observations | Brief Report
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2015, Volume 171, Issue 4, pp. 463 - 470
Summary We conducted a phase II study of the AKT inhibitor, MK2206 in patients with relapsed or refractory lymphoma of any histology excluding Burkitt lymphoma... 
clinical trials | AKT | lymphoma | target therapy | Clinical trials | Lymphoma | Target therapy | RAPAMYCIN | PI3K/AKT/MTOR | EVEROLIMUS RAD001 | CANCER | TRIAL | PATHWAY | TEMSIROLIMUS | IDELALISIB | GROWTH | MK-2206 | HEMATOLOGY | Recurrence | Humans | Middle Aged | Salvage Therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Hodgkin Disease - enzymology | Lymphoma - blood | Dose-Response Relationship, Drug | Young Adult | Lymphoma - drug therapy | Hyperglycemia - chemically induced | Lymphoma - therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Hodgkin Disease - drug therapy | Lymphoma - enzymology | Adult | Female | Cytokines - blood | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Disease-Free Survival | Feedback, Physiological | Hodgkin Disease - blood | Tumor Burden - drug effects | Protein Kinase Inhibitors - therapeutic use | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Aged | Gastrointestinal Diseases - chemically induced | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Medical research | Care and treatment | Relapse | Analysis | Medicine, Experimental | Lymphomas | Diseases | Index Medicus
Journal Article